Marisa Wexler, MS, senior science writer —

People with the rarest type of ANCA-associated vasculitis (AAV), called eosinophilic granulomatosis with polyangiitis (EGPA), and AAV patients with reduced kidney function are more likely to experience thrombosis (blood clots that disrupt blood flow), according to a single-center study in China. Results also indicated AAV patients with higher…

Biomarkers measured in blood or urine may help track disease activity and organ damage in people with ANCA-associated vasculitis (AAV), according to a systematic review study. AAV is an autoimmune disorder in which self-reactive antibodies called anti-neutrophil cytoplasmic antibodies (ANCAs) attack the body’s own neutrophils — a type of…

About half of people with granulomatosis with polyangiitis (GPA) have impairment of a valve in the heart, a study from Poland indicates. This heart valve dysfunction doesn’t cause notable problems for most patients, but a handful may have more severe complications that can require…

At ANCA Vasculitis News, we have spent the last year bringing you coverage of the latest developments in research and treatment for ANCA-associated vasculitis (AAV). Here, we’ve compiled a list of the top 10 most-read articles of 2023, with a brief description of each. We look forward to…

Self-reactive anti-neutrophil cytoplasmic antibodies, or ANCAs, may play a unique role in driving blood vessel inflammation in people with eosinophilic granulomatosis with polyangiitis (EGPA), the rarest form of ANCA-associated vasculitis (AAV). That’s according to a small study, which found that disease relapses outside the respiratory system occurred only in EGPA…

In a Phase 3 trial of Tavneos (avacopan) in people with ANCA-associated vasculitis (AAV), the therapy’s effectiveness in the subgroup of patients on standard induction treatment with rituximab was similar to that of the overall study population. Reasonable safety also was seen, and sustained one-year remission was higher…

The U.S. Food and Drug Administration has approved Sana Biotechnology’s investigational new drug (IND) application requesting a Phase 1 clinical trial of its investigational cell therapy SC291 in people with ANCA-associated vasculitis (AAV) and other autoimmune diseases. “Our goal is to develop SC291 for patients with multiple…

People with ANCA-associated vasculitis (AAV) that affects their kidneys are at a significantly increased risk of kidney failure if they show a high proportion of inflamed glomeruli (the organ’s filtering units) on biopsies collected at diagnosis, a study has found. The study, “Renal histopathological predictors of…

High blood levels of the immune protein C4 are significantly associated with greater kidney-specific disease activity and a higher chance of developing kidney failure with microscopic polyangiitis (MPA), the most common type of ANCA-associated vasculitis (AAV), a study shows. For this reason, measuring blood C4 levels may help predict…

A treatment regimen that combines low-dose glucocorticoids and rituximab is just as effective at controlling ANCA-associated vasculitis (AAV) as a standard regimen of high-dose glucocorticoids and rituximab, according to two-year data from a clinical trial. The long-term findings indicate that, while the efficacy is comparable, the risk of serious…